Literature DB >> 18301917

Recombinant viruses as tools to study human cytomegalovirus immune modulation.

Katrin Besold1, Bodo Plachter.   

Abstract

Infections with cytomegaloviruses are characterized by an intricate balance between the expression of immunomodulatory viral proteins and antiviral immune defence. For human cytomegalovirus (HCMV), several proteins have been described that interfere with the recognition of infected cells by CD8 T lymphocytes. Although the modes of action of these proteins have been elucidated on the molecular level, thus rendering them useful models to understand MHC class I peptide loading and transport, their role during viral infection has remained enigmatic. We exemplify here, how HCMV mutants can help to understand the importance of individual immunomodulatory proteins in the context of viral infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301917     DOI: 10.1007/s00430-008-0083-4

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  36 in total

1.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation.

Authors:  Christine S Falk; Michael Mach; Dolores J Schendel; Elisabeth H Weiss; Ivan Hilgert; Gabriele Hahn
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

Review 3.  Strategies for the identification and analysis of viral immune-evasive genes--cytomegalovirus as an example.

Authors:  A Gutermann; A Bubeck; M Wagner; U Reusch; C Ménard; U H Koszinowski
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

4.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.

Authors:  M J Reddehase; W Mutter; K Münch; H J Bühring; U H Koszinowski
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

6.  Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.

Authors:  Marcus-Folker Pahl-Seibert; Markus Juelch; Jürgen Podlech; Doris Thomas; Petra Deegen; Matthias J Reddehase; Rafaela Holtappels
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation.

Authors:  Christian O Simon; Rafaela Holtappels; Hanna-Mari Tervo; Verena Böhm; Torsten Däubner; Silke A Oehrlein-Karpi; Birgit Kühnapfel; Angélique Renzaho; Dennis Strand; Jürgen Podlech; Matthias J Reddehase; Natascha K A Grzimek
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

8.  Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants.

Authors:  E M Borst; G Hahn; U H Koszinowski; M Messerle
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 9.  Modulation of HLA expression in human cytomegalovirus immune evasion.

Authors:  Aifen Lin; Huihui Xu; Weihua Yan
Journal:  Cell Mol Immunol       Date:  2007-04       Impact factor: 11.530

10.  Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion.

Authors:  Katrin Besold; Nadine Frankenberg; Sandra Pepperl-Klindworth; Jürgen Kuball; Matthias Theobald; Gabriele Hahn; Bodo Plachter
Journal:  J Gen Virol       Date:  2007-05       Impact factor: 3.891

View more
  6 in total

Review 1.  Oncomodulation by human cytomegalovirus: evidence becomes stronger.

Authors:  Martin Michaelis; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

2.  Measurement of cytotoxic T lymphocyte activity of human cytomegalovirus seropositive individuals by a highly sensitive coupled luminescent method.

Authors:  Henry Ogbomo; Janina Geiler; Anke Leutz; Kristina von Kietzell; Martin Michaelis; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-10-08       Impact factor: 3.402

Review 3.  Oncomodulation by human cytomegalovirus: novel clinical findings open new roads.

Authors:  Martin Michaelis; Peter Baumgarten; Michel Mittelbronn; Pablo Hernáiz Driever; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2010-10-22       Impact factor: 3.402

4.  Human cytomegalovirus pp71 stimulates major histocompatibility complex class i presentation of IE1-derived peptides at immediate early times of infection.

Authors:  Julia Hesse; Sabine Reyda; Stefan Tenzer; Katrin Besold; Nina Reuter; Steffi Krauter; Nicole Büscher; Thomas Stamminger; Bodo Plachter
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

5.  Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.

Authors:  Véronique Mersseman; Verena Böhm; Rafaela Holtappels; Petra Deegen; Uwe Wolfrum; Bodo Plachter; Sabine Reyda
Journal:  Med Microbiol Immunol       Date:  2008-03-05       Impact factor: 3.402

6.  Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion.

Authors:  Stefanie Ameres; Josef Mautner; Fabian Schlott; Michael Neuenhahn; Dirk H Busch; Bodo Plachter; Andreas Moosmann
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.